These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30877503)

  • 1. A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance.
    El Rashedy AA; Appiah-Kubi P; Soliman MES
    Protein J; 2019 Apr; 38(2):142-150. PubMed ID: 30877503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
    Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
    Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1.
    Elrashedy AA; Ramharack P; Soliman MES
    Anticancer Agents Med Chem; 2019; 19(13):1642-1650. PubMed ID: 31250767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
    Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
    J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.
    Okamoto N; Yagi K; Imawaka S; Takaoka M; Aizawa F; Niimura T; Goda M; Miyata K; Kawada K; Izawa-Ishizawa Y; Sakaguchi S; Ishizawa K
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1214. PubMed ID: 39031848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
    Eide CA; Brewer D; Xie T; Schultz AR; Savage SL; Muratcioglu S; Merz N; Press RD; O'Hare T; Jacob T; Vu TQ; Tognon CE; Macey TA; Kuriyan J; Kalodimos CG; Druker BJ
    Cancer Cell; 2024 Sep; 42(9):1486-1488. PubMed ID: 39214096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
    Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
    Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
    G Lindström HJ; Friedman R
    BMC Cancer; 2020 May; 20(1):397. PubMed ID: 32380976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
    El Rashedy AA; Olotu FA; Soliman MES
    Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
    Leyte-Vidal A; DeFilippis R; Outhwaite IR; Kwan I; Lee JY; Leavitt C; Miller KB; Rea D; Rangwala AM; Lou K; Patel S; Alvarez A; Shokat KM; Bahar I; Seeliger MA; Shah NP
    Leukemia; 2024 Sep; 38(9):2046-2050. PubMed ID: 39085402
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.
    Zhang H; Zhu M; Li M; Ni D; Wang Y; Deng L; Du K; Lu S; Shi H; Cai C
    Front Pharmacol; 2022; 13():862504. PubMed ID: 35370687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
    Zhan JY; Ma J; Zheng QC
    J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.